ライフサイエンスコーパス: vasodilator

1 eptide (CGRP) is a potent neuromodulator and vasodilator.

2 Thus, CCt is a bi-modal vasodilator.

3 ptide (CGRP) is a potent arterial and venous vasodilator.

4 ction, although CCt was a far more effective vasodilator.

5 ionine gamma-lyase (CSE), is a proangiogenic vasodilator.

6 n pulmonary hypertension that functions as a vasodilator.

7 ts further implicate NO as a tonic pulmonary vasodilator.

8 rsisted despite administration of a coronary vasodilator.

9 permanent hypoxia to generate the metabolic vasodilators.

10 erity assessment without the need for potent vasodilators.

11 reater likelihood of stroke volume drop with vasodilators.

12 ility at rest and with endothelium-dependent vasodilators.

13 tion, vasopressors, inotropes, and pulmonary vasodilators.

14 cal treatment and injection of intraarterial vasodilators.

15 r both at rest and in response to endogenous vasodilators.

16 Nineteen studies (14 vasodilator, 4 dobutamine, and 1 that used both) involve

17 asopressors and/or inotropes, 9% versus 16%; vasodilators, 6% versus 12%; and any of these interventi

18 low in response to the endothelium-dependent vasodilator acetylcholine as well as the microvascular (

19 ng (1) infusion of the endothelium-dependent vasodilators acetylcholine (ACh) and adenosine triphosph

20 ng member of the conserved Ena/VASP (Enabled/Vasodilator Activated Protein) family is regulated by mi

21 sed expression of the focal adhesion protein vasodilator-activated phospho-protein (VASP), although t

22 din E synthase-1) depends critically for its vasodilator activity on the level of glutathione in the

23 e amplitude of the oscillations, whereas the vasodilator adenosine (ADO, 10(-4) M) reduced oscillatio

24 ntracted arterioles to endothelium-dependent vasodilators adenosine 5'-diphosphate (ADP) and substanc

25 iac MR imaging (at 1.5 T) at rest and during vasodilator (adenosine or regadenoson) stress, including

26 by a decrease in production of the pulmonary vasodilator adrenomedullin of almost 70% (P </= 0.05).

27 ch inhibition up-regulated the expression of vasodilators adrenomedullin and suppressed the expressio

28 Bradykinin (BK) is one of the most potent vasodilator agonists known and belongs to the kinin fami

29 ed by vascular endothelial cells is a potent vasodilator and an antiinflammatory mediator.

30 ossessing a signalling profile indicative of vasodilator and anti-fibrotic properties.

31 ning has beneficial impacts on radial artery vasodilator and constrictor function.

32 active Intestinal Peptide (VIP), a pulmonary vasodilator and inhibitor of vascular smooth muscle prol

33 Nitric oxide (NO), a potent vasodilator and nontraditional neurotransmitter, is an i

34 , suggests that intravascular ATP exerts its vasodilator and sympatholytic effects directly, and not

35 ular weight kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin

36 tors (GPCRs) contribute to the regulation of vasodilator and vasoconstrictor responses, and their act

37 Though modulated by endothelial-derived vasodilators and constrictors, O2 sensing is intrinsic t

38 phosphate-antagonist an adjunct therapy with vasodilators and gpIIb/IIIa inhibitors was given and rep

39 n impaired endothelium-dependent response to vasodilators and hyperresponse to vasoconstrictors.

40 mplications for care of older adults because vasodilators and oral beta-blockers are drugs that are u

41 have also investigated the role of pulmonary vasodilators and phosphodiesterase inhibitors in selecte

42 egments, whose contraction can be altered by vasodilators and vasoconstrictors.

43 d lipoxygenase metabolites prostaglandin E2 (vasodilator) and 12-hydroxyeicosatetraenoicacid (chemoat

44 unctional hyperemia), topical application of vasodilators, and decreases in blood pressure (CBF autor

45 Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could

46 es with established benefit in HFrEF such as vasodilators are frequently prescribed for HFpEF.

47 ty to endothelium-dependent and -independent vasodilators as well as vascular compliance in the setti

48 ggregometry (LTA), VerifyNow P2Y12 (VN), and vasodilator-associated stimulated phosphoprotein (VASP)

49 metry (LTA), VerifyNow P2Y12 (VN-P2Y12), and vasodilator-associated stimulated phosphoprotein (VASP).

50 y, exogenously administered nitrite is not a vasodilator at physiological concentrations in the vascu

51 e a number of other substrates including the vasodilator bradykinin and N-acetyl-Ser-Asp-Lys-Pro (Ac-

52 ion, not only because it can act as a potent vasodilator, but also because of its sympatholytic prope

53 ognized recently as an endothelium-dependent vasodilator, but several lines of evidence indicate that

54 poxia via the emission of multiple metabolic vasodilators by parenchymal cells.

55 ered in pathological states, we injected the vasodilator calcitonin gene-related peptide (CGRP), whic

56 The potent vasodilator calcitonin gene-related peptide mediates neu

57 Inhaled vasodilators can produce selective and potent pulmonary

58 CFR), which is a measure of overall coronary vasodilator capacity and microvascular function.

59 /NAD(P)Hoxidase protein ratio is a marker of vasodilator capacity.

60 arbon dioxide gas mixture, which is a potent vasodilator causing an increase of CBF.

61 t anterior descending artery (LAD) underwent vasodilator challenges with hypercapnia and adenosine.

62 p exercise (15% MVC), a control non-exercise vasodilator condition (adenosine), and ATP infusion in s

63 was calculated during 1) adenosine infusion (vasodilator control), 2) hypoxia (FIO2 = 10%), 3) endoto

64 ry drugs, aggressive analgesia, and possibly vasodilators could abort the crisis and prevent or minim

65 ha(1)-adrenoceptor stimulation is blunted by vasodilator COX products in young men and overcome by th

66 at O2 -dependent inhibition of production of vasodilator cyclooxygenase products or O2 -dependent des

67 ter the infusion of a 0.56 mg/kg dose of the vasodilator, dipyridamole, 3 serial whole-body PET scans

68 This endothelial vasodilator dysfunction during early diabetes may contri

69 d/-) mice, age-related endothelium-dependent vasodilator dysfunction in Xpd(TTD) animals was increase

70 Coronary vasodilator dysfunction is a powerful, independent corre

71 The vasodilator dysfunction was due to decreased endothelial

72 cell senescence, accelerated development of vasodilator dysfunction, increased vascular stiffness, a

73 rict fetal growth markedly augmented the UtA vasodilator effect of AMPK activation in opposition to P

74 Blocking adiponectin abolished the vasodilator effect of insulin in the presence of C57BL/6

75 w attenuated angiotensin (ANG)-(1-7)-induced vasodilator effect, endothelial nitric oxide synthase (e

76 , exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.

77 Enabled/Vasodilator (Ena/VASP) proteins promote actin filament a

78 pulmonary, but not systemic, effects of the vasodilators, fasudil and imatinib, in PAH rats.

79 vascular magnetic resonance (cine, T2* iron, vasodilator first pass myocardial perfusion, and late ga

80 ) without significant alterations in maximal vasodilator flow reserve.

81 mins (2C); more common use of inotropes and vasodilators for low cardiac output septic shock associa

82 (Vasodilator Free Measure of Fractional Flow Reserve [ADV

83 The instantaneous wave-free ratio (iFR) is a vasodilator-free pressure-only measure of the hemodynami

84 logical stimulus for enhancing microvascular vasodilator function in humans.

85 n whether noninvasive assessment of coronary vasodilator function in patients with suspected or known

86 Impaired vasodilator function is an early manifestation of corona

87 ischemia and increased oxidative stress, the vasodilator function of retinal arterioles was examined

88 no chronic effect on measures of endothelial vasodilator function was found.

89 Inter-relations of aortic stiffness and vasodilator function with incident CVD remain incomplete

90 invasive quantitative assessment of coronary vasodilator function with positron emission tomography i

91 yndrome is associated with impaired coronary vasodilator function, a marker of atherosclerotic diseas

92 y prevented the detrimental effect of CRP on vasodilator function, whereas anti-CD32 antibody treatme

93 ted with endothelial denudation and impaired vasodilator function, while postcatheterization exercise

94 tracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibitors, and anti

95 lure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to r

96 for age, gender, and other factors, using a vasodilator (hazard ratio [HR], 1.72; 95% confidence int

97 diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed d

98 th the levels induced by the ACE-independent vasodilator hydralazine.

99 er H/I, with the ERK isoform contributing to vasodilator impairment.

100 s, and the prodrug was shown to be an active vasodilator in rat isolated perfused kidneys (EC50 ~50 m

101 hypothesis that exogenous nitrite acts as a vasodilator in the cephalic vasculature of the intact, n

102 imately 70% and both oral spironolactone and vasodilators in approximately 90%, euvolemia was reached

103 e misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to incre

104 hance the pulmonary vascular effects of i.v. vasodilators in Sugen5416/hypoxia/normoxia-exposed PAH r

105 ssential because the initiation of pulmonary vasodilators in veno-occlusive disease often leads to in

106 neural activity or by endothelium-dependent vasodilators in WT mice but not in CD36-null mice (CD36(

107 timulates the expression of apelin, a potent vasodilator, in response to reduced blood arterial oxyge

108 ho do not respond to more traditionally used vasodilators include phosphodiesterase inhibitors and (f

109 Many vasodilators including angiotensin-converting enzyme inh

110 Use of inhaled vasodilators increased whereas use of prone position dec

111 Vasodilator-induced elevation of intracellular cyclic AM

112 The vasodilator-induced second messenger cAMP can relax vasc

113 t vasoconstriction to PE was observed during vasodilator infusion alone and mild exercise, and this w

114 the catheterization, pre-procedural systemic vasodilator infusion, and hemodialysis were independentl

115 ia, which was only resolved by intracoronary vasodilator injection.

116 Nitric oxide (NO) is a powerful vasodilator, involved in both physiological functions an

117 on and diminished effectiveness of CGRP as a vasodilator is multifaceted and may adversely affect spl

118 Use of vasodilators is associated with a 72% increase in the ha

119 S), a recently described endothelium-derived vasodilator, is produced by the enzyme cystathionine gam

120 Although pulmonary arterial vasodilators may often be considered in this setting, th

121 xus neurons and non-cholinergic secretomotor/vasodilator neurons in the submucosal plexus.

122 in neuropeptide Y-positive secretomotor and vasodilator neurons of the small intestine, but rarely w

123 The endogenous vasodilator nitric oxide (NO) is metabolized in tissues

124 synthase (eNOS), which generates the potent vasodilator nitric oxide (NO), is decreased.

125 increasing the bioavailability of the potent vasodilator nitric oxide (NO).

126 ly higher perfusate levels of the endogenous vasodilator nitric oxide.

127 e the bioactivity of the endothelium-derived vasodilator NO by enhancing NO synthesis or by decreasin

128 associated with weight loss, increase in the vasodilator NO, and decrease in lipid oxidation.

129 chiometrically reacts with and scavenges the vasodilator NO.

130 vasodilator-responsive IPAH (VR-PAH) versus vasodilator-nonresponsive IPAH (VN-PAH).

131 um channel blockers and better survival than vasodilator-nonresponsive PAH (VN-PAH).

132 e results demonstrate that H2S is a powerful vasodilator of the placental vasculature and that expres

133 Intrathecal administration of vasodilators or fibrinolytics may have offered advantage

134 dent increase in forearm blood flow with all vasodilators (P<0.001), which was attenuated by fire sim

135 ciated with greater adherence to recommended vasodilators (P=0.04).

136 crobials sanguinarine and berberine, and the vasodilator papaverine.

137 sistance, endothelial function, nitric oxide vasodilator pathway, apoptosis, inflammation, and liver

138 ed that abnormalities in endothelial-derived vasodilator pathways are temporally associated with the

139 Several vasodilator pathways have been proposed and examined as

140 sodium-potassium ATPase pump, two potential vasodilator pathways within blood vessels, contributes t

141 fter inhibiting shear- or pressure-dependent vasodilator pathways, and in mice with hindlimb ischemia

142 nsatory response through endothelial-derived vasodilator pathways.

143 e (NO) and prostacyclin trigger well-defined vasodilator pathways; however, substantial vasorelaxatio

144 Production of adrenomedullin (ADM), a vasodilator peptide, increases in response to ischemia a

145 t astrocyte calcium-evoked production of the vasodilator PgE2 is critically dependent on brain levels

146 flow (CBF) increases via the release of the vasodilator PgE2 We demonstrate that hypercapnia (increa

147 The vasodilator PGI(2) analog, cicaprost, increased Rap1 act

148 ded predictive value of specific assays (the vasodilator phosphoprotein assay for the clopidogrel res

149 Hydrogen sulfide (H(2)S) is a gaseous vasodilator produced by endothelial cells.

150 Conversely, endothelial-derived vasodilators progressively increased over 18 months and

151 e who received prone positioning vs. inhaled vasodilators (propensity score-adjusted hazard ratio for

152 olism, has shown nitric oxide (NO)-dependent vasodilator properties in experimental models.

153 Nitrite exhibits hypoxia-dependent vasodilator properties, selectively dilating capacitance

154 comitant positive inotropic, lusitropic, and vasodilator properties.

155 Vasodilator prostanoid contribution to endothelium-depen

156 Obese patients have impaired vasodilator reactivity and increased endothelin 1 (ET-1)

157 hat its actions are independent of the known vasodilator receptors of the RAS, Mas, and angiotensin I

158 We tested pulmonary vasodilator reserve using a soluble guanylate cyclase st

159 Myocardial blood flow (MBF) and vasodilator reserve were assessed by PET.

160 ith exercise, and depressed pulmonary artery vasodilator reserve.

161 A physically active lifestyle keeps both the vasodilator response and microvascular density high.

162 festyle keeps both microvascular density and vasodilator response high.

163 Thus, the attenuated skin vasodilator response in CHF patients is not attributable

164 poxic exercise only blunted the compensatory vasodilator response in the young group (P <0.05).

165 ary lifestyle, obesity and ageing impair the vasodilator response of the muscle microvasculature to i

166 s becoming increasingly apparent that a high vasodilator response of the skeletal muscle microvascula

167 pulmonary arterial hypertension (PAH), acute vasodilator response testing (AVT) is considered importa

168 At 1 week, the basal coronary flow and the vasodilator response to 5-hydroxytrytamine of syngeneic

169 to assess pulmonary endothelial function by vasodilator response to acetylcholine (Ach) administered

170 ring the control condition, the compensatory vasodilator response to hypoxia was similar between the

171 suggest that ageing reduces the compensatory vasodilator response to hypoxic exercise via blunted NO

172 ne the effects of ageing on the compensatory vasodilator response to hypoxic exercise we compared the

173 particulate pollution is not associated with vasodilator response, but that particulate air pollution

174 As ATP released from RBC is known to exert a vasodilator response, these results suggest a role for p

175 besity and ageing lead to impairments in the vasodilator response, while a physically active lifestyl

176 Vasodilator responses (%FVC) during intra-arterial ATP i

177 Vasodilator responses after inhibition of NO synthase bl

178 llow-up studies, BaCl(2) alone inhibited the vasodilator responses to ATP on average 51 +/- 3% (n = 6

179 ded a brachial arterial catheter for forearm vasodilator responses to isoprenaline with plethysmograp

180 ld influence the cardiovascular and regional vasodilator responses to sympathoexcitatory manoeuvres f

181 The vasodilator responses to three different doses of ATP we

182 ing IPAH and determine whether GVs differ in vasodilator-responsive IPAH (VR-PAH) versus vasodilator-

183 Although vasodilator-responsive PAH (VR-PAH) accounts for a minor

184 ncing age in humans, as evidenced by blunted vasodilator responsiveness to acetylcholine (ACh).

185 ndex in response to an endothelium-dependent vasodilator (salbutamol).

186 Acidosis is a powerful vasodilator signal in the brain circulation.

187 of cardiovascular health, yet the underlying vasodilator signaling pathways are controversial and thu

188 Thus, mechanisms of integration of vasodilator signalling across elements of the microvascu

189 ontraction) and in relation to the spread of vasodilator signals up- and downstream throughout the ne

190 6), 12 weeks of treatment with the pulmonary vasodilator sildenafil or placebo led to a 24.6% increas

191 substance P and the endothelium-independent vasodilator sodium nitroprusside (SNP) were examined.

192 phosphate (ATP), the endothelium-independent vasodilator (sodium nitroprusside, SNP), or potassium ch

193 schemia testing at 34 centers underwent rest/vasodilator SonoVue-enhanced flash-replenishment MCE, st

194 pulmonary hypertension that will complement vasodilator standards of care.

195 On-treatment vasodilator stimulated phosphoprotein P2Y(12) platelet r

196 Enabled/Vasodilator-stimulated phosphoprotein (Ena/VASP) protein

197 We used Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP)-deficie

198 The APC was not correlated with vasodilator-stimulated phosphoprotein (p = 0.16).

199 Vasodilator-stimulated phosphoprotein (VASP) and Ena-VAS

200 Vasodilator-stimulated phosphoprotein (VASP) can catalyz

201 (SH3), WW, GYF, and Drosophila enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP) homology 1

202 oncentrations nor induced phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in washed h

203 Vasodilator-stimulated phosphoprotein (VASP) is active i

204 n this study, we sought to determine whether vasodilator-stimulated phosphoprotein (VASP) signaling i

205 Targeted deletion of vasodilator-stimulated phosphoprotein (VASP), a key down

206 were induced by macrophage overexpression of vasodilator-stimulated phosphoprotein (VASP), a key down

207 ase G (PKG) and its downstream effector, the vasodilator-stimulated phosphoprotein (VASP).

208 sphorylation of the actin regulatory protein vasodilator-stimulated phosphoprotein (VASP).

209 Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphoryla

210 ost actin-regulatory layer containing zyxin, vasodilator-stimulated phosphoprotein and alpha-actinin.

211 partners alpha-actinin and p130Cas, but not vasodilator-stimulated phosphoprotein and cysteine-rich

212 thromboxane A(2) significantly decreased and vasodilator-stimulated phosphoprotein and nitric oxide i

213 ostanes, and thromboxane A(2), and increased vasodilator-stimulated phosphoprotein and nitric oxide.

214 sured by light transmittance aggregometry or vasodilator-stimulated phosphoprotein assays, was numeri

215 associated with fascin along the length and vasodilator-stimulated phosphoprotein at the tip.

216 pendent exocytosis of the late endosome in a vasodilator-stimulated phosphoprotein envelope.

217 sphate receptor blockade was assessed by the vasodilator-stimulated phosphoprotein index.

218 Pharmacodynamic end-points were vasodilator-stimulated phosphoprotein P2Y(12) platelet r

219 d or prevented by postsynaptic expression of vasodilator-stimulated phosphoprotein phospho-mimetic or

220 al cyclic adenosine monophosphate (cAMP) and vasodilator-stimulated phosphoprotein phosphorylation (V

221 d IPA was lower and P2Y12 reaction units and vasodilator-stimulated phosphoprotein phosphorylation an

222 Inhibition of vasodilator-stimulated phosphoprotein phosphorylation an

223 (P2Y12 assay) and platelet reactivity index (vasodilator-stimulated phosphoprotein phosphorylation as

224 PD was assessed by using VerifyNow P2Y12 and vasodilator-stimulated phosphoprotein phosphorylation as

225 d significant positive correlations with the vasodilator-stimulated phosphoprotein phosphorylation as

226 5 and 20 mumol/l and arachidonic acid), and vasodilator-stimulated phosphoprotein phosphorylation as

227 to dense granules, as confirmed by increased vasodilator-stimulated phosphoprotein phosphorylation in

228 and PKA, as determined by Rap1 activity and vasodilator-stimulated phosphoprotein phosphorylation, r

229 h using light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation.

230 production, cGMP synthesis, and PKG-induced vasodilator-stimulated phosphoprotein phosphorylation.

231 ith different agonists as well as changes in vasodilator-stimulated phosphoprotein platelet reactivit

232 esidual platelet aggregation, p = 0.005) and vasodilator-stimulated phosphoprotein platelet reactivit

233 icantly reduced the effect of clopidogrel on vasodilator-stimulated phosphoprotein platelet reactivit

234 ogaster Enabled (Ena) is a member of the Ena/vasodilator-stimulated phosphoprotein protein family, wh

235 Ras homolog gene family member A (RhoA) and vasodilator-stimulated phosphoprotein was increased in r

236 aramagnetic resonance and phosphorylation of vasodilator-stimulated phosphoprotein were determined.

237 eletal regulatory proteins of the Mena/VASP (vasodilator-stimulated phosphoprotein) family.

238 1) binding domains of Lpd and the host VASP (vasodilator-stimulated phosphoprotein) recruited to the

239 ated with increased mRNA expression of VASP (vasodilator-stimulated phosphoprotein).

240 as an established protein substrate of PKG (vasodilator-stimulated phosphoprotein).

241 of isoproterenol-induced phosphorylation of vasodilator-stimulated phosphoprotein, a membrane cytosk

242 Zyxin in turn recruits vasodilator-stimulated phosphoprotein, a regulator of ac

243 ion occurs because of associations involving vasodilator-stimulated phosphoprotein, focal adhesion ki

244 ion occurs because of associations involving vasodilator-stimulated phosphoprotein, focal adhesion ki

245 in in response to S-nitrosylation, including vasodilator-stimulated phosphoprotein, focal adhesion ki

246 Pharmacodynamic assessments measured by vasodilator-stimulated phosphoprotein, light transmittan

247 different assays, including VerifyNow P2Y12, vasodilator-stimulated phosphoprotein, light transmittan

248 let Nox2, Rac1, p47(phox), protein kinase C, vasodilator-stimulated phosphoprotein, nitric oxide, and

249 y Artery Bypass Graft (APTITUDE-CABG) study, vasodilator-stimulated phosphoprotein-platelet reactivit

250 s of the actin-binding protein, cofilin, and vasodilator-stimulated phosphoprotein-regulating conform

251 activation of cofilin 1 and inactivation of vasodilator-stimulated phosphoprotein.

252 al nitric oxide synthase, and phosphorylated vasodilator-stimulated phosphoprotein.

253 tions between the C-terminal EVH1 (Ena/VASP [vasodilator-stimulated phosphoprotein] homology domain 1

254 In this study, we found that vasodilator-stimulated protein (VASP) exhibits high affi

255 n=47) underwent CMR for assessment of DE and vasodilator stress ammonia positron emission tomography

256 Vasodilator stress cardiac MRI was performed in 118 wome

257 a (reduced perfusion and oxygenation) during vasodilator stress compared with normal volunteers.

258 dial perfusion and tissue oxygenation during vasodilator stress in patients with overt hypertrophic c

259 Myocardial perfusion under vasodilator stress is impaired in patients with HCM.

260 using (99m)Tc-tetrofosmin at rest and after vasodilator stress were performed using a dedicated cadm

261 g with (99m)Tc-sestamibi at rest and at peak vasodilator stress, followed by standard gated MPI.

262 CT evaluation of myocardial perfusion during vasodilator stress, thereby providing information about

263 erfusion and oxygenation are impaired during vasodilator stress.

264 ssue contrast is feasible at rest and during vasodilator stress.

265 Endothelium-dependent vasodilators, such as acetylcholine, increase intracellu

266 We evaluated the contribution of systemic vasodilators (SVD) to the management of DAA after OLT.

267 mportant building block for the synthesis of vasodilator taprostene.

268 Despite inpatient diuretics and vasodilators targeting decongestion, persistent congesti

269 tations were less likely to respond to acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907];

270 PH (r = -0.89), and acute reductions during vasodilator testing (r = -0.89, p </= 0.01 for all).

271 ry pressure and SCmin at baseline and during vasodilator testing (r=-0.81 and -0.85, respectively; P<

272 o cardiac output both at baseline and during vasodilator testing (r=-0.88 and -0.87, respectively; P<

273 ic PH (n = 22); and 3) changes in PVR during vasodilator testing in chronic PH (n = 10).

274 monary hypertension (PH) and the response to vasodilator testing require invasive right heart cathete

275 ute changes in pulmonary hemodynamics during vasodilator testing.

276 logical concentrations acted more as a local vasodilator that changed resting CBF and interfered with

277 al forces and, in response, releases various vasodilators that relax smooth muscle cells in a process

278 re information, more changes in diuretic and vasodilator therapies were made in the treatment group.

279 ility is modifiable with selective pulmonary vasodilator therapy and may represent an important targe

280 tudy was to compare hemodynamic responses to vasodilator therapy in patients with heart failure (HF)

281 dence-based treatment options, and pulmonary vasodilator therapy may lead to worsening symptoms.

282 correlated with the initiation of pulmonary vasodilator therapy post-PEA.

283 Treatment of hypertension with vasodilator therapy results in a lowering of the total L

284 n, peritoneal dialysis, oral sodium binders, vasodilator therapy, renal sympathetic denervation and a

285 t 3 to 5 years and did not require pulmonary vasodilator therapy.

286 odynamic testing prior to starting pulmonary vasodilator therapy; (3) differentiating PAH from pulmon

287 response of vascular beds to NO and NO-based vasodilators, thereby playing a central role in the regu

288 Because NO is a potent vasodilator, these neurons could translate neuronal sign

289 duced ejection fraction receiving aggressive vasodilator titration.

290 ng factors to resting and agonist-stimulated vasodilator tone in health and disease.

291 isease or lung disease, the use of pulmonary vasodilator treatment has not been proven to be safe and

292 e as an alternative to current pharmacologic vasodilators used for cardiac stress testing.

293 Consistent with the dual vasodilator/vasoconstrictor action of extracellular K(+)

294 ifference in efficacy, the EC50 of CGRP as a vasodilator was approximately 6-fold greater in Old vers

295 Pre-procedural use of pulmonary vasodilators was associated with reduced risk of composi

296 ,5'-cyclic guanosine monophosphate, a potent vasodilator, was greater in skin samples from null mice

297 ns of endothelial-dependent and -independent vasodilators were measured.

298 mited by the simultaneous release of several vasodilators with an effect size sequence of nitric oxid

299 Epoxyeicosatrienoic acids are vasodilators with anti-inflammatory properties that oppo

300 lizes the response of mesenteric arteries to vasodilators, with beneficial effects on portal hyperten